Journal of Antimicrobial Chemotherapy, Vol 39, 57-62, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
AM Sefton, JP Maskell, AM Rafay, A Whiley and JD Williams
The in-vitro activity of trovafloxacin, a new quinolone, was compared with
that of ciprofloxacin, erythromycin, various beta-lactam antibiotics and,
where appropriate, clindamycin and vancomycin against a range of
Gram-positive bacteria including staphylococci (n = 201), Streptococcus
pneumoniae (n = 83), beta-haemolytic streptococci (n = 46), viridans group
streptococci (n = 100), Streptococcus milleri (n = 18) and enterococci (n =
161) by an agar dilution technique. In addition, time-kill studies were
performed to estimate the bactericidal activity of trovafloxacin against S.
milleri and viridans group streptococci. Trovafloxacin was the most active
agent tested against staphylococci. It also showed good activity, at least
four-fold and usually eight- to 16-fold that of ciprofloxacin, against all
the streptococci. Trovafloxacin showed good activity against vancomycin-
sensitive Enterococcus faecalis and Enterococcus faecium, but was less
active against the 11 isolates of vancomycin-resistant enterococci.
Trovafloxacin showed comparable or superior bactericidal activity to
amoxycillin against the S. milleri and viridans group streptococci tested.
ORIGINAL ARTICLES
The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria
Department of Medical Microbiology, St Bartholomew's and the Royal London School of Medicine and Dentistry, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Diz Dios, I. Tomas Carmona, J. Limeres Posse, J. Medina Henriquez, J. Fernandez Feijoo, and M. Alvarez Fernandez Comparative Efficacies of Amoxicillin, Clindamycin, and Moxifloxacin in Prevention of Bacteremia following Dental Extractions. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2996 - 3002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hallgren, H. Abednazari, C. Ekdahl, H. Hanberger, M. Nilsson, A. Samuelsson, E. Svensson, L. E. Nilsson, and t. Swedish ICU Study Group Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems J. Antimicrob. Chemother., July 1, 2001; 48(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Aeschlimann, E. Hershberger, and M. J. Rybak Activities of Trovafloxacin and Ampicillin-Sulbactam Alone or in Combination versus Three Strains of Vancomycin- Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1153 - 1158. [Abstract] [Full Text]
|
|
|
|
|
|
S. N. Vostrov, O. V. Kononenko, I. Y. Lubenko, S. H. Zinner, and A. A. Firsov Comparative Pharmacodynamics of Gatifloxacin and Ciprofloxacin in an In Vitro Dynamic Model: Prediction of Equiefficient Doses and the Breakpoints of the Area under the Curve/MIC Ratio Antimicrob. Agents Chemother., April 1, 2000; 44(4): 879 - 884. [Abstract] [Full Text]
|
|
|
|
|
|
X.-Z. Li, L. Zhang, and K. Poole Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa J. Antimicrob. Chemother., April 1, 2000; 45(4): 433 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Gootz, R. P. Zaniewski, S. L. Haskell, F. S. Kaczmarek, and A. E. Maurice Activities of Trovafloxacin Compared with Those of Other Fluoroquinolones against Purified Topoisomerases and gyrA and grlA Mutants of Staphylococcus aureus Antimicrob. Agents Chemother., August 1, 1999; 43(8): 1845 - 1855. [Abstract] [Full Text]
|
|